

Atty Dkt. No.: STAN-110CON
USSN: 09/837,446

- A1 37. The method of claim 23, wherein the site of inflammation is a site of chronic inflammation.
38. The method of claim 23, wherein the site of inflammation is a site of an inflamed tonsil.

REMARKS**Formal Matters**

Claims 23-38 are pending after entry of the amendments set forth above.

Claims 1-22 are canceled without prejudice to renewal, and without intent to abandon any subject matter contained therein. Applicants expressly reserve the right to pursue the subject matter of the canceled claims in a continuing application.

Support for new claims 23-38 is found throughout the specification, including in the claims as originally filed. Specifically, support for new claims 23-38 may be found in the specification at the following positions: page 24 line 9 to page 25 line 23, page 6 lines 16 - 22, page 7 lines 9 - 11, page 11 lines 16 - 20, page 15 lines 15 - 17, and in Figures 1, 3, 5, 7, 8, and 9.

No new matter is added.

Restriction Requirement

In the Office Action dated May 22, 2002, the Examiner set forth a Restriction Requirement requiring election of one of the following groups of claims:

- Group I: Claims 1-9 and 13-17, drawn to a method of attracting systemic memory T cells by administering an agonist agent that is TARC.
- Group II: Claims 1-9 and 13-17 drawn to a method of attracting systemic memory T cells by administering an agonist agent that is MDC.
- Group III: Claims 1-7 and 10-21, drawn to a method of blocking trafficking of systemic memory T cells by administering an antagonist agent that is an antibody to CCR4.

Atty Dkt. No.: STAN-110CON
USSN: 09/837,446

- Group IV: Claims 1-7, 10-20 and 22, drawn to a method of blocking trafficking of systemic memory T cells by administering an antagonist agent that is an antibody to the CCR4 ligand TARC
- Group V: Claims 1-7, 10-20 and 22, drawn to a method of blocking trafficking of systemic memory T cells by administering an antagonist agent that is an antibody to the CCR4 ligand MDC.

Applicants hereby elect to prosecute the claims of Group III, claims 1-7 and 10-21, without traverse.

The newly presented claims 23-38 correspond to subject matter of Group III.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: September 19, 2002

By: James S. Keddie

James S. Keddie, Ph.D.
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENTS\TAN (Stanford)\110con\response to restriction requirement.doc